MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors

• No tumor spread to the brain

• Feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.)

• Available tumor tissue sample from prior surgery

• 4-6 weeks since prior therapy and recovered from prior therapy

• Men and women, ages 18 and above

• Women must not be pregnant or breastfeeding

• Diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular (liver) or renal (kidney) cancer

• Measurable disease on scans (at least one)